Vasogen raises $20.3m
This article was originally published in Clinica
Executive Summary
Vasogen, the Mississauga, Ontario-based developer of Celacade immunotherapy, has signed a deal to sell shares and warrants to raise US$20.3m. The company says the net proceeds of around $18.8m will be used for working capital, including the development of Celacade and its VP025 drug for neuroinflammatory disease.